This article is more than 5 years old. Information may no longer be current.

TranS1 receives CE Mark for lateral access fusion system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TranS1 Inc received CE Mark approval to market its VEO lateral access fusion system for interbody fusions in the European Union, according to a release.

Designed for direct visualization of the psoas muscles and adjacent nerves prior to muscle dissection, the VEO minimally invasive lateral system features a two-stage retraction method that focuses on nerve visualization and controlled reaction, the release noted. In addition to PEEK lateral interbody implants and ergonomic instruments, the device features radiopaque markers located within the implants to allow proper placement.

“We are very pleased to receive the CE mark for the VEO lateral system. This approval represents a significant milestone for TranS1 and will contribute to our efforts to become a leader in minimally invasive spine surgery,” Ken Reali, president and CEO of TranS1, stated in the release. “We are excited to begin executing on our commercialization strategy in Europe as we enter the third quarter.”